Bromodomain and extra-terminal  inhibitors—A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children—ACCELERATE

Based on biology and pre-clinical data, bromodomain and extra-terminal (BET) inhibitors have at least three potential roles in paediatric malignancies: NUT (nuclear protein in testis) carcinomas, MYC/MYCN-driven cancers  and fusion-driven malignancies. However, there are now at least 10 BET inhibitors in development, with a limited relevant paediatric population in which to evaluate these medicinal products. Therefore, a meeting was convened with the specific aim to develop a consensus among relevant biopharmaceut ical companies, academic researchers, as well as patient and family advocates, about the development of BET inhibitors, including prioritisation and their specific roles in children.

Source: European Journal of Cancer - February 16, 2021 Category: Cancer & Oncology Authors: Andrew DJ. Pearson, Steven G. DuBois, Vickie Buenger, Mark Kieran, Kimberly Stegmaier, Pratiti Bandopadhayay, Kelly Bennett, Franck Bourdeaut, Patrick A. Brown, Louis Chesler, Jessica Clymer, Elizabeth Fox, Christopher A. French, Eva Germovsek, Francis J. Tags: Review Source Type: research